I
n facial reconstructive surgery, new techniques based on the principles of tissue engineering have moved over the last decade from the bench closer to the bedside, where they are being combined with the principles of plastic surgery. In particular, mechanically competent cartilage grafts and osteoinductive constructs vascularized by flaps are envisioned to replace autologous or alloplastic materials, with the goal to reduce donor site morbidity and to increase graft durability. Here, we provide an overview of the state of the art in cartilage and bone tissue engineering and highlight how advances in this field might replace and improve current treatments in facial reconstructive surgery.
Trauma, cancer, or congenital abnormalities often lead to cartilaginous and bony defects in the head and neck region. These tissue losses can be replaced either by nonbiological materials (alloplastic implants) or by tissue transfer from a healthy site (autografts). Alloplastic implants (stainless steel, Dacron, or polyacrylates) are readily available and do not lead to donor site morbidity, but they are not long lasting and are associated with a high rate of complications, such as infection, chronic irritation, and sometimes even carcinogenicity. Autologous tissue reconstruction is the prevalent and most versatile option in facial reconstructive surgery but is limited by the availability of donor tissue, morbidity at the donor site, and time-consuming surgery. The field of tissue engineering aims at generating fully biocompatible grafts in sufficient amounts, meeting the requirements of the repair site and avoiding the considerable donor site morbidity associated with traditional reconstructive techniques.
Tissue Engineering of Cartilage
The goal of cartilage tissue engineering in facial reconstructive surgery is to generate a graft that can be implanted at different sites of the head and neck by applying the same surgical techniques as in reconstruction using autologous grafts. Engineering of a cartilage graft would start from obtaining a small biopsy from the nasal septum, ear, or rib cartilage. This procedure can be performed under local anaesthetic in a minimally invasive fashion and will not lead to donor site morbidity, as does the harvest of large grafts for reconstructive purposes. After enzymatic digestion of the specimen, the cells would be expanded in vitro and then induced to grow on bioactive degradable scaffolds that provide the structural and biochemical cues to guide their differentiation and generate a three-dimensional (3-D) tissue. Such a construct would then be transplanted into the defect, where further cell differentiation and tissue integration is expected to occur.
Cell Sources
External ear [1] and nasal [2] , [3] chondrocytes have been used with various degrees of success to engineer in vitro and/or in vivo 3-D cartilaginous tissues. Taking both cell yields and proliferation rates into account, we recently reported that a biopsy of human ear, nasal, or rib cartilage, weighing a few milligrams, would yield tens of millions of cells over a two-to three-week period [4] . This number of cells, based on reported seeding densities of nonarticular chondrocytes into various 3-D scaffolds, would be sufficient for the generation of autologous grafts of clinically relevant size (i.e., greater than 1 cm 2 in size). But the key point is the chondrogenic capacity of these cells, because chondrocytes dedifferentiate to a fibroblastic stage during monolayer expansion. Although in principle, redifferentiation can be achieved upon transfer into a 3-D culture environment, the potential of human expanded chondrocytes to redifferentiate and generate a functional matrix is limited and decreases with donor age. To overcome these limitations, specific regulatory molecules (e.g., growth factors, hormones, metabolites) have been employed as medium supplements during the different culture phases. Results indicate that expansion of chondrocytes in the presence of growth factors not only increases the cell proliferation rate, but also maintains the ability of the cells to redifferentiate upon transfer into a 3-D environment [5] and to subsequently respond to differentiating agents [6] . At present, however, we could not find in the literature a comparative animal or clinical study involving the use of chondrocytes expanded under conditions favoring cell proliferation and maintenance of chondrogenic ability.
An alternative to the use of differentiated chondrocytes is the use of cells with chondrogenic differentiation capacity, like mesenchymal progenitor cells (MPCs). MPCs can be isolated, for instance, from bone marrow aspirates and have the potential to differentiate into various mesenchymal tissue lineages [7] . Despite the reports that MPCs can generate cartilaginous tissues [8] , [9] , the molecules expressed indicate possible instability of the cartilage phenotype, associated with remodeling of the engineered cartilage into a mineralized tissue. Moreover, no report has been published so far regarding the preclinical or clinical use of MPC in facial cartilage reconstruction.
3-D Scaffolds
Another critical element in engineering cartilage is a suitable scaffold that displays biological and physical properties matching both the needs of differentiating chondrocytes in vitro and of regenerating cartilage in vivo. The scaffold must provide sufficient mechanical strength and stiffness to substitute initially for wound contraction forces and, later, for the remodeling of the tissue. Furthermore, it should enhance cell attachment and provide enough space to J. Farhadi, C. Jaquiery, M. Haug, G. Pierer, HF. Zeilhofer, and I. Martin allow the exchange of nutrients and waste products and the deposition of extracellular matrix. In addition, the mechanical characteristics of the scaffold should be such that at the time of implantation the cell-scaffold construct can sustain the surgical manipulation and the insertion of sutures.
Different research groups have used a wide variety of scaffolds in an attempt to generate cartilaginous tissues in vitro [10] . The form and composition of these scaffolds range from nonwoven meshes and foams of alpha-hydroxypolyesters, polyglactin, or hyaluronan alkyl esters to photo-crosslinked hydrogels and sponges based on different types of collagen and glycosaminoglycans. Composites consisting of a 3-D porous scaffold filled with cells embedded in a fibrin or alginate gel have also been explored. But many of these scaffolds are still in the experimental evaluation, and several issues still have to be addressed, related to the interactions between cells and specific substrates, the influence of the pore size distribution on cell behavior, and the effect of scaffold geometry (i.e., in the form of a foam, mesh, or gel) on the induction/ maintenance of the chondrocytic phenotype [11] .
Upscaling of the Constructs
One of the major challenges in cartilage tissue engineering is the generation of uniform tissues of clinically relevant size (i.e., a few square centimeters in area and 3-4 mm in thickness). An upscaling of the constructs could be reached by the use of bioreactors, where cell seeding and culture may be facilitated by the application of mechanical and/or hydrodynamic forces [12] . Bioreactors would also provide a controlled in vitro environment over specific biochemical and physical signals, which have the potential to regulate chondrogenesis and improve the structure and function of the resulting cartilage tissues [13] - [15] . Despite the great efforts currently dedicated to the development and use of bioreactors for the engineering of functional cartilage tissue, it is still rather unclear which specific physical stimulation regime is required to induce a specific effect on cultured chondrocytes.
Tissue Engineering of Bone
The goal of bone tissue engineering in facial reconstructive surgery is to generate an osteoinductive graft, namely, a construct that upon implantation in the area to be reconstructed is capable of initiating the formation of bone tissue. The engineering of an osteoinductive graft of predefined size and shape can be achieved by loading a 3-D osteoconductive scaffold with either osteogenic cells or bone morphogenetic proteins. According to the former approach, osteogenic cells are obtained from biopsies of diverse possible tissues (e.g., bone marrow, periosteum) and are typically expanded in culture. The latter approach appears more simple, since it does not require ex vivo cell processing but opens the biological question of how the overdose of one single molecule could recapitulate the complex set of molecular events physiologically involved in the safe and stable formation of bone tissue.
Cell Sources
It has been demonstrated that the regeneration of critically sized bone defects in a sheep model can be achieved by combining osteogenic cells and a ceramic scaffold, whereas the ceramic scaffold alone leads to less uniform and less efficient ossification [16] . This and other recent studies support the necessity of delivering viable osteogenic cells within a ceramic scaffold in order to achieve a stable and load-bearing osseous formation and integration. MPCs isolated from the bone marrow are currently the most widely used cell source for the experimental induction of bone tissue formation, which has also been tested in few clinical cases [17] . However, considering the conditions required for bone marrow harvest and that the amount of MPCs that can be isolated is limited and highly variable [18] , attempts have been made to isolate MPCs from alternative tissues. Dragoo et al. isolated human MPCs from fat tissue and from bone marrow aspirates and compared the osteogenic potential of both cell sources when transfected with adenovirus containing BMP-2 [19] . Fat-tissue-derived transfected MPCs showed faster osteogenic differentiation as compared with MPCs extracted from bone marrow, although more recent communications indicate that MPCs from fat tissue are a reliable osteogenic cell source only if associated with the delivery of osteoinductive genes/proteins. The periosteum from the jaws can easily be harvested under local anesthesia and in an outpatient environment. Schantz and associates demonstrated in vitro osteogenic differentiation of periosteum-derived osteoprogenitor cells and ectopic in vivo bone formation using a nude mouse model [20] . Recently, Schimming and Schmelzeisen reported the clinical use of periosteal cells in combination with a polymer fleece in the context of the maxillary sinus elevation procedure [21] . In a series of 27 patients, 18 showed bone formation six months after operation. However, it remains unclear whether the detected bone was formed by periosteal cells or by the cells surrounding the defect.
3-D Osteoconductive Scaffolds
Support of bone regeneration by osteoconductive materials is a procedure that has been used in surgery for decades to restore parts of the facial skeleton. Due to excellent vascularization of the head and neck, incorporation of these materials in general is efficient, and the potential risk of infection is low, as compared to other sites of the body. Osteoconductive materials are biomaterials that support adhesion, proliferation, and differentiation of osteogenic cells from surrounding tissues, ultimately leading to bone tissue formation. After an ideal time frame of a few months, the scaffold should be replaced by newly formed bone, undergoing subsequent integration and remodeling. In addition to animal or human bone-derived scaffolds, two main groups of synthetically manufactured osteoconductive materials can be identified: the ceramics and the synthetic polymers. The criteria for the selection of osteoconductive materials should be based on the ability to support differentiation of osteogenic cells, on the rate of resorption, and on Cellular/Tissue Engineering (continued) the possibility of applying rapid prototyping techniques in order to fully control the architecture and the outer design of the scaffold. Ceramics are well known to support the osteogenic phenotype of osteoblasts [22] and can prime the differentiation of MPCs toward the formation of bone tissue [23] . Even if it seems possible to design a standardized hydroxyapatite ceramic scaffold with the help of rapid prototyping techniques [24] , the architecture of a given scaffold (i.e., the size and the interconnectivity of the pores), as well as the mechanical properties, is generally better controlled using synthetic polymers [25] . The ability of synthetic polymers to induce osteogenic cell differentiation is, on the other hand, generally lower than that of ceramics, unless growth factors are incorporated and released in a controlled fashion.
Growth Factors
Urist first popularized the concept of a bone-generating protein in 1965 when he made the discovery of bone morphogenetic proteins (BMP) [26] . The BMP family includes the most commonly used molecules for musculoskeletal tissue regeneration. In principle, the following three different concepts for the use of growth factors are envisioned in bone tissue engineering. First, a specific growth factor can be applied during culture of osteogenic cells to enhance proliferation and/or differentiation; these cells, combined with an osteoconductive scaffold, can then be implanted as an osteoinductive graft. Second, the desired growth factor may be injected directly at the site together with an osteoconductive material, aiming at recruitment and differentiation of MPCs localized in the neighboring original bone or muscle tissue. Third, a specific growth factor can be incorporated within a polymer scaffold, which, by degradation, will release the factor with defined kinetics.
Vascularization and Integration
Due to excellent vascularization of the head and neck area, even large segmental defects of the jaws can be reconstructed by the use of free nonvascularized bone grafts. This favorable situation would also allow the use of large engineered grafts for the reconstruction of jaws, minimizing the potential risk of failing integration. In case of insufficient vascularization of the recipient bed, the formation of new blood vessels bringing nutrients to the engineered graft could be promoted by 1) the delivery of angiogenic factors, 2) the generation of artificial microvascular networks, or 3) the prefabrication of flaps.
The use of angiogenic factors is gaining increasing attention by the scientific community but requires definition and control of the appropriate timing and dose of the specific factors. Indeed, it has been recently demonstrated that a longterm continuous delivery of vascular endothelial growth factor (VEGF) by transfected myoblasts can lead to normal vascularization, but only if levels are maintained below a microenvironmental threshold [27] . The generation of microvascular networks by the insertion of a vascular pedicel into the engineered tissue, buried subcutaneously, is an interesting, innovative strategy that is currently being explored in a variety of models [28] . The prefabrication of a flap in combination with engineered osteoinductive grafts has been recently described for the reconstruction of almost an entire lower jaw using bovine bone-derived ceramic, BMP-2, and MPCs harvested from the bone marrow [29] . After designing the jaw with the help of 3-D imaging, these components were implanted subcutaneously in the back of the patient, and six weeks later, the graft was transferred microsurgically along with the latissimus dorsi muscle. At first glance, it seems appealing to transfer the engineered graft together with an excellent vascularized muscle. However, taking into account that the harvesting procedure of the latissimus dorsi muscle may cause considerable donor site morbidity, the advantages of the previously described procedure are questionable.
Advances for Clinical Application and Future Horizons
In this article, we have reviewed some of the techniques that are being developed to manipulate human chondrocytes and MPCs to generate cartilaginous and osteoinductive tissues. Considering that engineered cartilage and bone tissues in reconstructive surgery of the head and neck would have to restore form and function, the main challenges in the future will be related to improving methods to define the shape and stage of development of the engineered tissues. Moreover, since the clinical use of engineered tissues in facial reconstructive surgery is, so far, anecdotal, it will also be critical to identify which surgical procedures will first benefit from the advances in tissue engineering.
Cartilage grafts for nasal reconstructive surgery probably will be the first application in the clinics, as these grafts have to be fairly small and, after implantation, would be embedded in a well vascularized bed. Furthermore, the nose is not subjected to high mechanical stresses directly after implantation of a graft; therefore, the graft does not need to be fully structurally stable. Similar considerations are valid for reconstruction of the eyelids. Instead, the clinical use of engineered ear cartilage grafts is expected to be more complex, as in most clinical situations there is the need to reconstruct a soft-tissue defect next to the cartilage defect. Furthermore, ear cartilage has a more complex anatomical shape, and the engineered ear cartilage may need to be created by computer-aided design (CAD) templates. An important issue for the clinical use of engineered cartilage in facial and reconstructive surgery will be to identify the structural and functional properties of the tissue engineered grafts, which need to be matched for the efficacy and safety of the implantation.
The reconstruction of bone defects in the head and neck region by engineered grafts is already close to clinical applications. One of the main problems in bone tissue engineering is to induce rapid vascularization when a certain size of the constructs is reached. As the engineering of a vascular tissue is not yet achievable, the combination of tissue engineering techniques with flap surgery could bridge this gap and lead to the clinical application of engineered bone in facial reconstruction. Furthermore, imaging techniques combined with computational modeling and fabrication of scaffolds through rapid prototyping techniques are likely to play an important role, as the facial bones have complex 3-D structures [25] .
One major challenge for the routine clinical use of engineered tissues is related to the manufacturing process, which at present is costly, impractical, and not sufficiently standardized. In this context, we envision that 3-D tissues could be engineered within closed bioreactor units with advanced control systems that would facilitate streamlining and automation of the numerous labor-intensive steps. Starting from a patient's tissue biopsy, a bioreactor system could isolate, expand, seed on a scaffold, and differentiate specific cell types, thereby performing the different processing phases within a single closed and automated system [12] . Such a bioreactor would enable competent hospitals and clinics to carry out autologous tissue engineering for their own patients, eliminating logistical issues of transferring specimens between locations. This would also eliminate the need for large and expensive GMP (good manufacturing practice) tissue engineering facilities and minimize operator handling, with the final result of reducing the cost of tissue engineered products for the health system and for the community.
Altogether, when efficiently designed for low-cost operation, novel bioreactor systems could facilitate spreading novel and powerful cell-based tissue engineering approaches, which would otherwise remain confined within the context of academic studies or restricted to elite social classes or systems.
